Product Description
Levodopa is the precursor to dopamine. Most commonly, clinicians use levodopa as a dopamine replacement agent for the treatment of Parkinson's disease. It is most effectively used to control bradykinetic symptoms that are apparent in Parkinson's disease. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK482140/)
Mechanisms of Action: DR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Parkinson Disease | Parkinson Disease | Parkinson Disease | Parkinson Disease
Known Adverse Events: Respiratory Tract Infections | Hypotension | Hypotension, Orthostatic | Parkinson Disease | Dizziness | Headache | Insomnia | Constipation | Hypertension | Depressive Disorder | Pain Unspecified | Erythema | Edema | Dyskinesias
Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, India, Italy, Japan, Luxembourg, Spain
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Parkinson's Disease
Phase 1: Acute Respiratory Distress Syndrome|Dyskinesias|Parkinsonian Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2015-005814-31 | P2 |
Active, not recruiting |
Parkinson's Disease |
2025-02-28 |
|
| NCT06037590 | P1 |
Completed |
Parkinson's Disease|Parkinsonian Disorders |
2023-10-20 |
|
| DD701105 | P1 |
Completed |
Dyskinesias|Parkinson's Disease |
2022-11-30 |
43% |
| DD701105 | P1 |
Completed |
Dyskinesias|Parkinson's Disease |
2022-11-30 |
43% |
| SCOL | P2 |
Completed |
Parkinson's Disease |
2022-07-21 |
32% |